Cohance Lifesciences shares experienced a 20% increase, reaching ₹432.70 on the Bombay Stock Exchange (BSE), following the announcement of Umang Vohra as Executive Chairman effective May 1, 2026, and Group CEO effective May 20, 2026. This surge comes as the company's trading volumes tripled, with 14.71 million shares exchanged on the National Stock Exchange (NSE) and BSE. The stock has rebounded 62% from its 52-week low of ₹267.85, which it reached on March 9, 2026. Vohra, who previously served as CEO of Cipla, is expected to lead Cohance's transformation into a leading technology-driven Contract Development and Manufacturing Organisation (CDMO). Cohance operates in three segments: pharma CRDMO, specialty chemicals, and high-potent active pharmaceutical ingredients (APIs), with a notable presence in the regulated markets of the US and Europe, where 87% of its revenue was generated in FY25. The company is focused on growth in high-value niches, including antibody-drug conjugates (ADCs) and aims to file five to ten products annually in its formulations segment to enhance its market position.